Hookipa Pharma Inc News Today

Royal Bank of Canada reissued their outperform rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a report published on Tuesday morning, Benzinga reports. The firm currently has a $5.00 price target on the stock. Separately, HC Wainwright reduced their target price on shares of Hookipa Pharma from $6.50 to $5.00 and set […]

Royal Bank of Canada reaffirmed their outperform rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has a $5.00 price target on the stock. Separately, HC Wainwright reduced their price target on shares of Hookipa Pharma from […]

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or...

NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...

HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority...

Hookipa Pharma Inc (NASDAQ:HOOK – Free Report) – Research analysts at HC Wainwright boosted their Q1 2024 earnings per share (EPS) estimates for shares of Hookipa Pharma in a research report issued on Monday, March 25th. HC Wainwright analyst A. He now forecasts that the company will earn ($0.18) per share for the quarter, up […]

Hookipa Pharma Inc (NASDAQ:HOOK – Free Report) – Equities researchers at HC Wainwright issued their FY2028 earnings per share estimates for shares of Hookipa Pharma in a report released on Monday, March 25th. HC Wainwright analyst A. He forecasts that the company will post earnings of $0.31 per share for the year. HC Wainwright currently […]

Hookipa Pharma Inc.’s nearly $1 billion collaboration with Roche Holding AG dissolved along with 30% of the company’s staff. The New York-based company said Roche ended the October 2022 deal involving the HB-700 program in treating KRAS mutated cancers but did not say why the agreement fell apart.

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious...

Shares of Hookipa Pharma Inc (NASDAQ:HOOK – Get Free Report) were down 16.5% during mid-day trading on Monday . The stock traded as low as $0.71 and last traded at $0.72. Approximately 9,262,100 shares were traded during trading, an increase of 749% from the average daily volume of 1,090,797 shares. The stock had previously closed […]